– Phase II acute pain program to initiate in September – Ended quarter with $50 million in cash and equivalents, providing over two years of runway TORONTO–(BUSINESS WIRE)–$ATBPF–Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies that target inflammation, has filed its financial … [Read more…]
Plenity Q2 product revenue increased 312% year-over-year to $9.0 million Gross profit in Q2 increased by $4.0 million year-over-year, with gross margin improving to 47% from 8% BOSTON–(BUSINESS WIRE)–Gelesis (NYSE: GLS), the maker of Plenity for weight management, today reported financial results for the second quarter of 2022. “We are seeing both consumers and clinicians … [Read more…]
DUBLIN–(BUSINESS WIRE)–The “Large Joint Devices Market Report Suite – Global – 2022-2028 – MedSuite” report has been added to ResearchAndMarkets.com’s offering. The total Global Large Joint Devices Market is growing at a rate of 4.8%, which will take the 2021 market value of $19 billion up to $26 billion by 2028. One of the top … [Read more…]
ForGround offers tools, resources, and discounts to advance the adoption of climate smart practices that can transform value chains Potential benefits from transitioning to regenerative agriculture may include improved soil health1, reduced water use2, fewer inputs3, increased weather resiliency4 and less soil erosion5 The platform has been built on Bayer’s years of experience and knowledge … [Read more…]
Results consistent with previous trials, reinforcing benefit of Daiichi Sankyo and AstraZeneca’s ENHERTU in previously treated patients TOKYO & MUNICH & BASKING RIDGE, N.J.–(BUSINESS WIRE)–Positive topline results from the DESTINY-Breast02 phase 3 trial of ENHERTU® (trastuzumab deruxtecan) versus physician’s choice of treatment showed the trial met the primary endpoint, demonstrating a statistically significant and clinically … [Read more…]
All claims made by Seagen regarding Daiichi Sankyo antibody drug conjugates are denied TOKYO & MUNICH & BASKING RIDGE, N.J.–(BUSINESS WIRE)–An arbitrator issued a decision today in a dispute between Daiichi Sankyo Company, Ltd. and Seagen, Inc., denying all claims made by Seagen. Specifically, Daiichi Sankyo retains all patent rights to its antibody drug conjugate … [Read more…]
BOSTON–(BUSINESS WIRE)–Karuna Therapeutics, Inc. (NASDAQ: KRTX) (“Karuna”), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced the closing of its previously announced upsized underwritten public offering of 4,011,628 shares of common stock, including the exercise in full by the underwriters of their option … [Read more…]
HALIFAX, Nova Scotia–(BUSINESS WIRE)–Appili Therapeutics Inc. (TSX:APLI; OTCQX: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced its financial and operational results for the first quarter of its fiscal year 2023, which ended on June 30, 2022. “As threats from both known and emerging infectious … [Read more…]
FOSTER CITY, Calif.–(BUSINESS WIRE)–Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the identification, acquisition, development and commercialization of novel therapies for debilitating rare and orphan diseases, today announced the closing of its previously announced underwritten public offering of 4,000,000 shares of its common stock, including the exercise in full by the underwriters of … [Read more…]
ALAMEDA, Calif.–(BUSINESS WIRE)–AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for the quarter ended June 30, 2022. Liquidity and Capital Resources During the first quarter of 2022, AgeX borrowed the final $0.5 million of its available credit under its 2020 … [Read more…]
